



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
23.06.2021 Bulletin 2021/25

(45) Date of publication and mention
of the grant of the patent:
19.05.2021 Bulletin 2021/20

(21) Application number: **19186196.2**

(22) Date of filing: **17.11.2015**

(51) Int Cl.:
A61K 9/00 ^(2006.01) **A61K 31/428** ^(2006.01)
A61K 9/20 ^(2006.01) **A61K 9/08** ^(2006.01)
A61K 47/20 ^(2006.01) **A61K 47/26** ^(2006.01)
A61P 25/00 ^(2006.01) **A61P 25/16** ^(2006.01)
A61P 25/18 ^(2006.01) **A61P 25/22** ^(2006.01)
A61P 25/24 ^(2006.01) **A61P 25/28** ^(2006.01)
A61P 25/30 ^(2006.01)

(54) **SUBLINGUAL FORMULATION OF RILUZOLE**
SUBLINGUALE FORMULIERUNG VON RILUZOL
FORMULATION SUBLINGUALE DE RILUZOLE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **21.11.2014 US 201462083094 P**

(43) Date of publication of application:
04.03.2020 Bulletin 2020/10

(60) Divisional application:
21169884.0

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
15823415.3 / 3 220 891

(73) Proprietor: **Biohaven Pharmaceutical Holding
Company Ltd.**
New Haven, CT 06520 (US)

(72) Inventors:
• **CORIC, Vladimir**
Madison, CT 06443 (US)

• **BERMAN, Robert, M.**
New Haven, CT 06511 (US)
• **VLADYKA, Ronald, Samuel**
Somerst
NJ 08873 (US)
• **SALEH, Amgad**
Dayton
NJ 08810 (US)
• **YU, Danny**
Somerville
MA 08876 (US)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

(56) References cited:
WO-A2-2013/010015 CA-A1- 2 864 008
US-A1- 2014 371 277

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).